RAIN · Rain Oncology Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.96M | $14.98M | $16.68M | - | $14.51M | $14.26M | $13.55M | - | $15.28M | $5.49M |
| SG&A | $4.11M | $5.41M | $5.07M | - | $3.90M | $3.46M | $3.90M | - | $591.0K | $1.12M |
| Total Operating Expenses | $8.08M | $23.23M | $21.74M | - | $18.41M | $17.72M | $17.45M | - | $18.44M | $2.59M |
| D&A | $18.0K | $22.0K | $18.0K | - | - | - | $22.0K | - | - | - |
| Operating Income | ($8.08M) | ($23.23M) | ($21.74M) | - | ($18.41M) | ($17.72M) | ($17.45M) | - | ($18.44M) | ($2.59M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | $33.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.03M) | ($22.06M) | ($20.48M) | - | ($18.04M) | ($17.61M) | ($17.39M) | - | ($18.43M) | ($2.62M) |
| EPS - Basic | ($0.19) | ($0.61) | ($0.66) | - | ($0.68) | ($0.66) | - | - | - | - |
| EPS - Diluted | ($0.19) | ($0.61) | ($0.56) | - | ($0.68) | ($0.39) | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.31M | $40.08M | $44.10M | $61.95M | $39.83M | $43.41M | $21.50M | $24.78M | $13.26M | $118.01M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.97M | $5.80M | $7.42M | $7.15M | $4.08M | $2.08M | $3.03M | $6.11M | $3.68M | $3.90M |
| Current Assets | $80.82M | $90.99M | $112.97M | $133.63M | $93.75M | $109.61M | $126.83M | $146.15M | $157.41M | $173.26M |
| Total Assets | $82.06M | $91.72M | $114.18M | $135.18M | $94.64M | $110.66M | $127.78M | $147.14M | $158.53M | $174.55M |
| Current Liabilities | $14.48M | $18.33M | $19.48M | $21.97M | $13.01M | $12.13M | $13.04M | $16.32M | $10.90M | $9.34M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $14.54M | $18.43M | $19.62M | $22.14M | $13.23M | $12.38M | $13.33M | $16.64M | $11.26M | $9.72M |
| Stockholders' Equity | $67.52M | $73.29M | $94.56M | $113.04M | $81.41M | $98.28M | $114.45M | $130.50M | $147.28M | $164.83M |
| Retained Earnings | ($215.27M) | ($208.24M) | ($186.17M) | ($165.69M) | ($143.01M) | ($124.97M) | ($107.36M) | ($89.96M) | ($71.98M) | ($53.55M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($21.84M) | - | - | - | ($17.11M) | - | - | - |
| Investing Cash Flow | - | - | $3.52M | - | - | - | $13.44M | - | - | - |
| Financing Cash Flow | - | - | $466.0K | - | - | - | $399.0K | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.6% | -24.1% | -17.9% | - | -19.1% | -15.9% | -13.6% | - | -11.6% | -1.5% |
| Return on equity | -10.4% | -30.1% | -21.7% | - | -22.2% | -17.9% | -15.2% | - | -12.5% | -1.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.58 | 4.96 | 5.80 | 6.08 | 7.20 | 9.04 | 9.72 | 8.96 | 14.44 | 18.56 |
| Quick ratio | 5.58 | 4.96 | 5.80 | 6.08 | 7.20 | 9.04 | 9.72 | 8.96 | 14.44 | 18.56 |
| Cash ratio | 2.58 | 2.19 | 2.26 | 2.82 | 3.06 | 3.58 | 1.65 | 1.52 | 1.22 | 12.64 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | -78.5x |
| Equity multiplier | 1.22 | 1.25 | 1.21 | 1.20 | 1.16 | 1.13 | 1.12 | 1.13 | 1.08 | 1.06 |
| Liabilities / Assets | 0.18 | 0.20 | 0.17 | 0.16 | 0.14 | 0.11 | 0.10 | 0.11 | 0.07 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 56.1% | -31.1% | -24.6% | - | 0.1% | -583.6% | -618.1% | - | - | - |
| Net income growth (YoY) | 61.0% | -25.3% | -17.8% | - | 2.1% | -571.2% | -577.1% | - | - | - |
| EPS growth (YoY) | 72.1% | -56.4% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -17.1% | -25.4% | -17.4% | -13.4% | -44.7% | -40.4% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Rain Oncology Inc. against the 5 most active filers in the same SIC group.